Donald Santel
Director/Board Member chez AEROVATE THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Donald J.
Santel was the founder of CoTherix, Inc. founded in 2000, where he served as Chief Executive Officer & Director until 2007.
He currently holds three positions as Chairman at Tentarix Biotherapeutics LP, Ocelot Bio, Inc., and as an Independent Director at Aerovate Therapeutics, Inc. He has also served as a Director at Arête Therapeutics, Inc., Abilitech Medical, Inc., and ChemGenex Pharmaceuticals, Inc. Santel's education includes an undergraduate degree from Purdue University and a graduate degree from the University of Minnesota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Donald Santel
| Sociétés | Poste | Début |
|---|---|---|
| AEROVATE THERAPEUTICS, INC. | Director/Board Member | 19/01/2023 |
Tentarix Biotherapeutics LP
 Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | Chairman | 20/05/2022 |
Ocelot Bio, Inc.
 Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Chairman | 01/06/2021 |
Anciens postes connus de Donald Santel
| Sociétés | Poste | Fin |
|---|---|---|
| OYSR POIN | Chairman | 03/01/2023 |
| SURROZEN, INC. | Director/Board Member | 01/08/2021 |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Chief Executive Officer | 06/05/2019 |
| HYPERION THERAPEUTICS INC | Chief Executive Officer | 07/05/2015 |
| ANTHERA PHARMACEUTICALS, INC. | Director/Board Member | 08/05/2012 |
Formation de Donald Santel
| Purdue University | Undergraduate Degree |
| University of Minnesota | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| AEROVATE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Medtronic, Inc.
 Medtronic, Inc. Medical SpecialtiesHealth Technology Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN. | Health Technology |
Cardiac Pathways Corp.
 Cardiac Pathways Corp. Medical SpecialtiesHealth Technology Cardiac Pathways Corp. designs, develops and manufactures cardiac diagnosis systems. Its products consist principally of systems for performing ablation treatment and for diagnostic mapping. Cardiac Pathways is located in Sunnyvale, CA. | Health Technology |
CoTherix, Inc.
 CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Health Technology |
Arête Therapeutics, Inc.
 Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
ChemGenex Pharmaceuticals Pty Ltd.
 ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Health Technology |
ChemGenex Pharmaceuticals, Inc.
 ChemGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA. | Health Technology |
CardioVasc, Inc.
 CardioVasc, Inc. Industrial SpecialtiesProcess Industries CardioVasc, Inc. manufactured biomimetic coating products, which is covalently bonded to the surface of a device and is designed to promote rapid healing. It was used in the treatment of diseased saphenous vein grafts, aneurysms and perforations. The company was headquartered in Menlo Park, CA | Process Industries |
| Reflow, Inc. | |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Health Technology |
NeuroRecovery Technologies, Inc.
 NeuroRecovery Technologies, Inc. Medical SpecialtiesHealth Technology NeuroRecovery Technologies, Inc. designs and develops devices and applications to help restore function & movement in patients with paralysis. It provides non-invasive external system, a class II non-significant risk device, for individuals with partial to complete paralysis and implantable system used to optimally treat individuals with severe motor paralysis who do not respond to transcutaneous device. The company was founded by Nick Terrafranca Jr. and is headquartered in San Juan Capistrano , CA. | Health Technology |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
Abilitech Medical, Inc.
 Abilitech Medical, Inc. Medical/Nursing ServicesHealth Services Abilitech Medical, Inc. provides solution to restore function and independence to those affected by neuromuscular conditions. Its product portfolio include Abilitech Assist, Abilitech Medical AbiliGrip, and AbiliGrasp Robotic Assist. The company was founded by Angie Zavoral Conley in 2016 and is headquartered in Eden Prairie, MN. | Health Services |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Consonance-HFW Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisitions, share purchase, reorganization, or similar business combination. The company was founded by Gad Soffer and Kevin Harold Livingston on August 21, 2020 and is headquartered in Princeton, NJ. | Finance |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Health Technology |
